Genprex Inc
$ 0.65
-6.95%
05 Jun - close price
- Market Cap 6,846,200 USD
- Current Price $ 0.65
- High / Low $ 0.70 / 0.63
- Stock P/E N/A
- Book Value 2.42
- EPS -5.06
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.76 %
- ROE -1.61 %
- 52 Week High 55.00
- 52 Week Low 0.63
About
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company is headquartered in Austin, Texas.
Analyst Target Price
$7.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-30 | 2025-11-14 | 2025-08-14 | 2025-04-07 | 2025-03-31 | 2024-11-13 | 2024-08-09 | 2024-05-15 | 2024-03-29 | 2023-11-14 | 2023-08-21 | 2023-05-22 |
| Reported EPS | -1.1515 | -5 | -8.47 | -0.26 | -0.4242 | -1.23 | -3 | -3.69 | -3.96 | -0.13 | -0.15 | -0.19 |
| Estimated EPS | None | -0.65 | -0.74 | -2.54 | -0.39 | -1.93 | -2.3 | -2.54 | -3.93 | -0.11 | -0.12 | -0.12 |
| Surprise | 0 | -4.35 | -7.73 | 2.28 | -0.0342 | 0.7 | -0.7 | -1.15 | -0.03 | -0.02 | -0.03 | -0.07 |
| Surprise Percentage | None% | -669.2308% | -1044.5946% | 89.7638% | -8.7692% | 36.2694% | -30.4348% | -45.2756% | -0.7634% | -18.1818% | -25% | -58.3333% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: GNPX
2026-06-05 21:08:47
Genprex, Inc. has filed an S-3 shelf registration to offer up to $250 million in various securities, including common stock, preferred stock, warrants, debt securities, subscription rights, and units. This filing replaces a previous registration and carries forward over $76 million in unsold securities. The net proceeds are intended for working capital and general corporate purposes, such as R&D, clinical trials, and potential acquisitions, with specific allocations to be detailed in future prospectus supplements.
2026-05-27 11:38:53
Genprex (NASDAQ: GNPX) reported positive biomarker data from its Reqorsa gene therapy at the 2026 ASCO Annual Meeting, indicating that higher Trop-2 H-scores and lower PTEN H-scores correlate with longer progression-free survival in non-small cell lung cancer (NSCLC) patients. The findings, based on data from 18 lung cancer patients, suggest potential for targeted patient selection and personalized medicine in NSCLC, although these correlations were not observed in small cell lung cancer (SCLC) patients. Despite the positive clinical data, the company's stock experienced a decline, fitting a historical pattern of negative market reactions to clinical news.
2026-05-26 14:09:30
Genprex, Inc. announced positive clinical data presented at the 2026 ASCO Annual Meeting concerning predictive biomarkers for its lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), in lung cancer treatment. Studies showed that higher levels of Trop-2 H-scores and lower PTEN H-scores correlated with prolonged progression-free survival (PFS) in patients with Non-Small Cell Lung Cancer (NSCLC). This research suggests that high Trop-2 expression could serve as a valuable biomarker for Reqorsa® in NSCLC patients.
2026-05-26 12:09:30
Genprex, Inc. announced positive clinical data from studies of predictive biomarkers in patients receiving Reqorsa® Gene Therapy for lung cancer, presented at the 2026 ASCO Annual Meeting. The research indicates that high Trop-2 levels and low PTEN levels correlate with longer Progression Free Survival in Non-Small Cell Lung Cancer (NSCLC) patients treated with REQORSA, suggesting potential for personalized medicine. The company plans further studies to optimize patient selection based on these biomarker findings.
2026-05-26 12:09:30
Genprex (NASDAQ: GNPX) has released new biomarker data from its Acclaim clinical trials for Reqorsa gene therapy in lung cancer patients. The data, presented at the 2026 ASCO Annual Meeting, indicate that higher Trop-2 H-scores and lower PTEN H-scores correlate with longer progression-free survival (PFS) in Non-Small Cell Lung Cancer (NSCLC) patients. The company plans further investigation into high Trop-2 expression as a potential biomarker for Reqorsa.
2026-05-16 07:40:08
Genprex announced that its collaborators presented positive preclinical data on their diabetes gene therapy, GPX-002 (Pdx1/MafA gene therapy), at the 2026 ASGCT Annual Meeting. The data showed that the gene therapy reversed hyperglycemia in Type 2 diabetic mouse models by enhancing beta-cell function and maturation. This preclinical success represents a significant step towards a potential long-term treatment for Type 2 diabetes.
